This week on BioTech Nation, Sean Ainsworth, CEO of ImmuSoft, explains how modifying the body’s own B cells to produce therapeutic proteins could revolutionize drug delivery. From improving treatment for rare diseases like Hurler syndrome to potentially replacing injections for autoimmune and metabolic conditions, this new approach opens the door to long-term, patient-specific solutions.
This week on BioTech Nation, Dr. Thomas Chen, Director of Neuro-Oncology at USC and Founder of NeOnc Technologies, shares treating glioblastoma by delivering a drug directly to the brain through nasal inhalation changes the drug delivery game, bypassing the blood-brain barrier. This technique is achieving results in clinical trials.
This week on BioTech Nation, I speak with Dr. John Cumbers, founder and CEO of SynBioBeta, the annual synthetic biology conference. We discuss how biology, AI, and technology are transforming industries, covering tracks on human health, planetary health, and hyperscale biology. SynBioBeta 2025 will take place in San Jose, CA, from May 5 to 8.
This week on BioTech Nation, Ossium Health co-founder and CEO Kevin Caldwell shares how their breakthrough approach is changing bone marrow transplants. By cryobanking marrow from organ donors, Ossium is reducing wait times, improving access, and preparing for future emergencies. With support from BARDA and promising clinical trial results, this new system could help thousands more receive lifesaving transplants—right when they need them.
This week on BioTech Nation, we explore what happens when your immune system overreacts. Professor Niels Riedemann, CEO of InflaRx, explains how the body’s defense system can sometimes cause more harm than good, leading to serious conditions like rheumatoid arthritis, severe COVID-19, and lung failure. Learn how InflaRx is developing treatments to calm the immune system and why their breakthrough drug is getting attention from U.S. health agencies.
This week on BioTech Nation, Dr. Daniel Kraft explores how smarter design can make healthcare easier, less stressful, and more effective. From hospitals built for patient comfort to medical apps that adapt to your needs, the way we experience healthcare is evolving. Learn how design thinking and empathy are shaping the future of medicine.
This week on BioTech Nation, Catalyst Pharmaceuticals CEO Rich Daly discusses the complexities of treating epilepsy and rare diseases. From the challenges of polypharmacy—where patients need multiple drugs to manage a single condition—to the hurdles of diagnosing and treating ultra-rare diseases.
This week on Biotech Nation, Dr. Ari Azhir, Founder and CEO of Neuvivo, shares the incredible journey of an ALS drug that was once abandoned, but is now making its way toward FDA approval. After two failed phase two trials, the drug was left behind until Dr. Azhir and her team discovered a crucial mistake in the trial data. Now with new insights and groundbreaking survival results, Neuvivo is giving hope to ALS patients and exploring its potential for other neurodegenerative diseases like Huntington’s and Alzheimer’s.
This week on BioTech Nation, Dr. Daniel Kraft explores the discovery of "dark" proteins, thousands of previously unknown proteins in the human body. Scientists believe these hidden proteins could be the key to detecting diseases earlier and developing new treatments.
This week on Biotech Nation, Dr. Lincoln Nadauld shares how Culmination Bio is using 9 million preserved tissue samples and decades of patient data to improve how we understand and treat diseases. From discovering patterns in cancer treatments to exploring breakthroughs in heart and autoimmune diseases, this unique approach is changing medicine.
This week on Biotech Nation, Dr. Daniel Kraft discusses why mobility is emerging as a key indicator of health, just like heart rate or blood pressure. From wearable tech that tracks your gait to AI-powered exoskeletons and brain-computer interfaces, new innovations are transforming how we measure and maintain movement.
This week on Biotech Nation, Dr. Martin Borch Jensen and Dr. Francisco LePort from Gordian Biotechnology share a bold new approach to fighting diseases of aging before they take hold. Instead of testing one drug at a time, their technology allows scientists to test hundreds of potential treatments at once, making drug discovery faster and more precise. This could change how we treat conditions like arthritis, heart failure, and fatty liver disease.
Not just seeking treatment for every disease, but making sure the treatments we have already developed are being used in every possible way. I speak with Dr. David Fajgenbaum (Fay-gen-baum), a Professor of Translational Medicine and Human Genetics at the University of Pennsylvania School of Medicine, and President of Every Cure.
This week on Biotech Nation, Priovant Therapeutics CEO Ben Zimmer shares how their once-a-day pill could transform the treatment of severe autoimmune diseases like dermatomyositis and non-infectious uveitis. With phase 3 trials in progress, Priovant is offering hope to patients with few modern treatment options.
In this week's episode of BioTech Nation, Dr. David Bearss, President and CEO of Halia Therapeutics, discusses inflammation and its reduction over a lifetime and in response to various incidents. He unveils the inflammasome, a recently discovered protein complex critical in regulating inflammatory responses and its potential in treating chronic diseases like myelodysplastic syndrome and Alzheimer's. Dr. Bearss shares insights into Halia's groundbreaking approach and his relentless pursuit of medical breakthroughs.
Dr. Jim Brown from DURECT talks about their clinical trials for Alcohol-Associated Hepatitis, a condition for which there is no approved treatment.
Sir Rory Collins is a Professor of Medicine and Epidemiology at the University of Oxford and the Principal Investigator of the UK Biobank. With data from half a million people, it has served 30,000 scientists around the world, giving special support to young researchers and scientists in emergent countries.
When is a medical technology company more than a medical technology company? We’ll hear all about it when I speak with Dave Pacitti, the President and Head of the Americas at Siemens Healthineers. They’re out to solve problems bigger than the products they are known for.
Major Depressive Disorder. Serious Depression. PTSD. Alto Neuroscience CEO, Dr. Amit Etkin talks about developing new and innovative drugs tied directly to each patient’s underlying biology. For every drug, there is a test...
Discover how their AI technology is revolutionizing drug discovery with Dr. Vimal Mehta, Co-Founder and CEO BioXcel and how this is leading to the approval of their first drug for agitation in bipolar I and II and schizophrenia, and paving the way for new treatments.
